Skip to content
Screener

MoonLake Immunotherapeutics MLTX Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$348.72M+58.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$15.19B—

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.55B-54.2%
Enterprise value$1.36B-57.1%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 8:55 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001821586-26-000007
(in thousands)March 31, 2026 / Amortized costMarch 31, 2026 / Gross unrealized gainsFair value
Eurocommercial Papers$29,536$181$29,717
Certificates of Deposit29,53318129,714
Total$59,069$362$59,431
Of which classified within short-term marketable debt securities59,06936259,431

Item 1. Financial Statements (Unaudited)

FAQ

What is MoonLake Immunotherapeutics's cash, cash equivalents, and marketable securities?
MoonLake Immunotherapeutics (MLTX) reported cash, cash equivalents, and marketable securities of $59.43M in Q1 2026.
How has MoonLake Immunotherapeutics's cash, cash equivalents, and marketable securities changed year-over-year?
MoonLake Immunotherapeutics's cash, cash equivalents, and marketable securities decreased by 71.5% year-over-year, from $208.56M to $59.43M.
What does cash, cash equivalents, and marketable securities mean?
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.

Ask your AI about MoonLake Immunotherapeutics's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude